Transactional

Rethinking the Growth Capital Challenge in UK Life Sciences

Matthew Appleton

Investors, entrepreneurs and deal makers in the UK Life Sciences industry met on the 28 September 2018 to share ideas on how to close the funding gap which exists for UK businesses in the period between early stage investment and IPO. At a lively panel discussion sponsored by LSX Connect and hosted by Allen & Read More

Life Sciences IPOs – 5 things to consider

Michael Bloch

After spending all day last Wednesday at Biotech & Money’s IPO workshop presenting and talking to Life Sciences start ups about their IPO plans, we thought it might be interesting to bring together some of our key thoughts on IPO preparedness. Companies thinking about an IPO can never start planning too early.  IPO planning and Read More

Beyond the pill – are digital health deals set to spike?

Matthew Appleton

Transactions between big pharmaceutical companies and start-ups working on potentially highly disruptive but beneficial technologies in the healthcare space have not taken off as fast as some expected. That could be about to change. It probably wasn’t meant to take centre stage, but the small white circle on the arm of UK Prime Minister Theresa Read More

Pension funds to catalyse growth in Life Sciences companies?

Matthew Appleton

We’ve seen a lot of activity in the past week around how the UK government plans to galvanise growth in innovative companies (summary here). As I wrote a couple of months ago, only by focusing on all stages in the growth cycle of a Life Sciences company can four £20bn+ UK companies be created in Read More

Life Sciences M&A in a holding pattern

Matthew Appleton

Continued uncertainty surrounding President Trump’s proposed tax reforms has slowed activity in the Life Sciences sector, with deal values holding well below the record levels seen in previous years. If Trump’s promised corporate tax cut materialises, big U.S. players may be encouraged to repatriate (and spend) the huge amounts of cash currently held offshore.  But Read More